Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 5/20 | 0.40 |
| ▸ | METAP2 | P50579 | 5/20 | 0.38 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19330608 | 0.97 | CXCR2 (0.38) | CXCR2METAP2CXCR5SORT1CFTR | |
| SCHEMBL12500989 | 0.80 | METAP2 (0.40) | METAP2DRD2HTR1DDRD3TP53 | |
| SCHEMBL7676369 | 0.80 | CXCR5 (0.37) | CXCR2CXCR5CFTRDRD2HTR1D | |
| SCHEMBL20956566 | 0.80 | DRD2 (0.38) | CFTRDRD2HTR1DDRD3TP53 | |
| SCHEMBL19330864 | 0.78 | CFTR (0.38) | CXCR2CFTR | |
| SCHEMBL21834481 | 0.77 | MEN1 (0.41) | CXCR2CXCR5POLB | |
| SCHEMBL18529854 | 0.76 | PDK2 (0.44) | CXCR2CFTR | |
| SCHEMBL19330640 | 0.75 | TRIM24 (0.33) | CXCR2CFTRDRD2POLB | |
| SCHEMBL6197535 | 0.75 | LMNA (0.42) | CFTRPOLB | |
| SCHEMBL30888601 | 0.75 | BDKRB1 (0.35) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | SLC6A4, HTR3C, HTR3A | CXCR2 2304/4885METAP2 1527/4885CXCR5 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.